WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

AN OPEN LABEL, BALANCED, RANDOMISED, FOUR-TREATMENT, FOUR-PERIOD, FOUR-SEQUENCE, SINGLE INTRA-ORAL AND ORAL DOSE, CROSSOVER PHARMACOKINETICS STUDY OF WD-1603 EXTENDED-RELEASE CARBIDOPA/LEVODOPA TABLETS 25/100MG IN NORMAL, HEALTHY, ADULT HUMAN SUBJECTS UNDER FASTING AND FED CONDITIONS

The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics

Study Overview

• Status: Unknown
• Conditions: Parkinson Disease
• Intervention / Treatment: Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

• Study Type: Interventional
• Enrollment (Anticipated): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• India
  • Ahmedabad, India
    • Recruiting
    • Lambda Therapeutic Research Ltd.
    • Contact: Alpesh Jaswantlal Parmar, Doctor; Phone Number: + 91-79-40202020; Email: alpeshjparmar@lambda-cro.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).
2. Having a Body Mass Index (BMI) between 18.5 to 29.9 (both inclusive), calculated as weight in kg / height in m2.
3. Not having any significant disease or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG and X-ray chest (P/A view) recordings.
4. Able to understand and comply with the study procedures, in the opinion of the principal investigator.
5. Able to give voluntary written informed consent for participation in the trial.
6. In case of female subjects:

a. Surgically sterilized at least 6 months prior to study participation or If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.

And b. Serum Pregnancy test must be negative.

Exclusion Criteria:

1. Known hypersensitivity or idiosyncratic reaction to Carbidopa or Levodopa or any of the excipients or any related drug.
2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
3. Ingestion of a medicine (prescribed & over the counter (OTC) medication including herbal remedies) at any time within 14 days before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.
4. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
5. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
6. A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period I.
7. Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.
8. The presence of clinically significant abnormal laboratory values during screening.
9. History or presence of psychiatric disorders.
10. A history of difficulty in donating blood.
11. Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.

12. Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication**.

    ** If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.

13. A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.
14. A positive test result for HIV (1 &/or 2) antibody.
15. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medicine in period I. In any such case subject selection will be at the discretion of the Principal Investigator.
16. Consumption of grapefruit or grapefruit products within 72 hours prior to dosing in period-I.
17. Difficulty in swallowing oral solid dosage form like tablets or capsules.
18. Nursing mothers (females).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Treatment A; Treatment A will be given under fed conditions by intra-oral single dose administration	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS; CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
EXPERIMENTAL: Treatment B; Treatment B will be given intra-orally and orally under fed conditions by single dose administration	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS; CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
EXPERIMENTAL: Treatment C; Treatment C will be given orally under fed conditions by single dose administration	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS; CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
EXPERIMENTAL: Treatment D; Treatment D will be given orally under fasting conditions by single dose administration	Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS; CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Pharmacokinetics Measurements to Determine Cmax for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations	Day 1 and Day 2
AUC0-t	Pharmacokinetics Measurements to Determine AUC0-t for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations	Day 1 and Day 2
AUC0-∞	Pharmacokinetics Measurements to Determine AUC0-∞ for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations	Day 1 and Day 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tmax	Pharmacokinetics Measurements to Determine Tmax for Carbidopa (CD) and	Day 1 and Day 2
t1/2	Pharmacokinetics Measurements to Determine t1/2 for Carbidopa (CD) and	Day 1 and Day 2

Collaborators and Investigators

• Sponsor: Hong Kong WD Pharmaceutical Co., Limited

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 13, 2020
• Primary Completion (ANTICIPATED): September 5, 2020
• Study Completion (ANTICIPATED): February 13, 2021

Study Registration Dates

• First Submitted: August 12, 2020
• First Submitted That Met QC Criteria: August 12, 2020
• First Posted (ACTUAL): August 14, 2020

Study Record Updates

• Last Update Posted (ACTUAL): September 10, 2020
• Last Update Submitted That Met QC Criteria: September 9, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Dopamine Agents; Antiparkinson Agents; Anti-Dyskinesia Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Levodopa; Carbidopa
• Other Study ID Numbers: WD-1603-1002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No